Market News & Trends
AIM ImmunoTech Submits Pre-IND Application to the FDA for Phase 2 Clinical Study of Ampligen as a Potential Infusion Therapy for Post-COVID-19 Cognitive Dysfunction
AIM ImmunoTech Inc. recently announced it has submitted a Pre-Investigational New Drug application (Pre-IND) to the US FDA for a Phase 2 clinical study of…
Soleno Therapeutics Announces Positive Data Showing Continued Significant Improvements in Symptoms of PWS Following 1 Year Treatment With DCCR
Soleno Therapeutics, Inc. recently announced top-line results from the company’s ongoing open-label extension study, C602, evaluating investigational, once-daily DCCR (Diazoxide Choline) Extended-Release tablets for patients…
Celsion Reports T-cell & B-cell Response From In Vivo Studies With its PLACCINE DNA Vaccine Platform
Celsion Corporation recently announced results from preclinical in vivo studies showing production of antibodies and cytotoxic T-cell response specific to the spike antigen of SARS-CoV-2…
TCR² Therapeutics Receives FDA Orphan Drug Designation for Gavo-cel for the Treatment of Cholangiocarcinoma
TCR2 Therapeutics Inc. recently announced the US FDA has granted the company Orphan Drug Designation (ODD) to gavo-cel for the treatment of cholangiocarcinoma. New clinical…
Adamis Pharmaceuticals Doses First Patients in Phase 2/3 Clinical Trial for Tempol in the Treatment of COVID-19
Adamis Pharmaceuticals Corporation recently announced the initiation of patient dosing in the Phase 2/3 clinical trial for Tempol, an oral antiviral product candidate, in adult patients…
Genezen Appoints New CEO as GMP Expansion Begins
Genezen Inc., a cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has appointed Ray Kaczmarek as CEO. Mr. Kaczmarek has over 28 years…
Sterling Pharma Solutions Awarded Gold Medal by EcoVadis, Recognizing Achievements in Sustainability
Sterling Pharma Solutions recently announced it has been awarded a gold medal by EcoVadis, in recognition of the company’s sustainability management system through its policies,…
A Collaborative Effort Paves the Way for a New Approach to Small Batch Manufacturing
In today’s pharmaceutical industry there is a sharp focus on the needs and requirements of the patient. More and more drugs are being developed for specific patient groups. Orphan drugs, for example,….
Pardes Biosciences Initiates First-in-Human Trial for PBI-0451, an Oral Antiviral in Development to Treat & Prevent SARS-CoV-2 Infections
Pardes Biosciences, Inc. recently announced the initiation of a Phase 1 clinical trial, evaluating the company’s lead candidate, PBI-0451 which is being developed as a potential oral….
Jasper Health & BioIntelliSense Form Strategic Collaboration to Transform Remote Monitoring for Oncology Care
Jasper Health recently announced it has formed a strategic collaboration with BioIntelliSense, a continuous health monitoring and clinical intelligence company, to integrate its medical grade….
Fusion Antibodies Partners With Eurofins Discovery to Support Innovative Preclinical Drug Discovery Research
Fusion Antibodies plc recently announced it has entered into a commercial collaboration with Eurofins, a Eurofins Scientific SE (EUFI.PA) group company; a leading provider of products and services to the….
Adhera Therapeutics Signs Exclusive License Agreement With Melior Pharmaceuticals I for New Type 1 Diabetes Drug Candidate
Adhera Therapeutics, Inc. recently announced it has executed an exclusive license agreement with Melior Pharmaceuticals I, Inc. defining the terms and conditions for which Adhera will license MLR-1023….
Poseida Therapeutics Announces FDA Clearance of IND Application for Allogeneic CAR-T Candidate for Relapsed/Refractory Multiple Myeloma
Poseida Therapeutics, Inc. recently announced the US FDA has cleared its Investigational New Drug (IND) application for P-BCMA-ALLO1, the company's first fully allogeneic CAR-T product…
Nuvectis Pharma Raises $15 Million & In-Licenses Exclusive Worldwide Rights to Novel Selective HSF1 Pathway Inhibitor From the CRT Pioneer Fund
Nuvectis Pharma, Inc. recently announced the completion of a $15-million Series A Preferred Stock financing with institutional and private investors. Nuvectis also announced that it…
Diffusion Pharmaceuticals Announces Clearance of IND Application for TSC by FDA’s Pulmonology, Allergy & Critical Care Division
Diffusion Pharmaceuticals Inc. recently announced it has obtained clearance of its Investigational New Drug (IND) application submitted to the US FDA Pulmonology, Allergy, and Critical…
Aerami Therapeutics Announces Orphan Drug Designation for Imatinib for the Treatment of Pulmonary Arterial Hypertension
Aerami Therapeutics, Inc. recently announced the US FDA has granted the company orphan drug designation for imatinib for treatment of patients with pulmonary arterial hypertension…
Quantum Genomics Presents Results From Phase 2b QUORUM Study of Firibastat in Heart Failure
Quantum Genomics recently announced results of the Phase 2b QUORUM study were presented by Prof. Gilles Montalescot (Paris) on August 27, 2021 during the 2021…
AC Immune Announces First Positive Cognitive Results for a Tau-Targeting Monoclonal Antibody in Alzheimer’s Disease
AC Immune SA recently announced Genentech, a member of the Roche Group, has informed the company that Lauriet, a placebo-controlled Phase 2 study evaluating the…
Quotient Sciences Announces Multimillion-Pound Investment in Drug Substance Manufacturing Facility
Quotient Sciences, the drug development and manufacturing accelerator, recently announced a £6.3 million-pound investment in its recently acquired manufacturing facility in Alnwick, UK…..
Mitsubishi Chemical Advanced Materials to Become Climate Neutral by 2023 & Targets Climate Positivity by 2030
Mitsubishi Chemical Advanced Materials AG (MCAM), a leading global manufacturer of high-performance materials, is proud to announce its goal to achieve climate positivity in its…
